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The chemotactic deactivation of human monocytes was studied to provide
insight into the mechanism of chemotaxis. Deactivation was dependent on the
dose of chemoattractant and time of incubation. A concentration in the cell
suspension of 10' M N-formylmethionylleucyl phenylalanine (FMLP) for 45 min
at 370C led to 60% suppression of the subsequent specific chemotactic response.
Higher concentrations of FMLP led to almost 100% specific suppression. Deacti-
vation was specific under all conditions used. The response to a nonrelated
chemoattractant, human serum-derived C5a, was unaffected by incubation in
FMLP. Deactivation was also transient. If cells were deactivated at 370C with
FMLP, they recovered within 6 h at 370C from this deactivation. Both phenom-
ena, deactivation and recovery from deactivation, were temperature dependent.
Monocytes could not be deactivated at 00C, and they did not recover from
deactivation when kept at 00C. Thus, specific deactivation appears to require
cellular metabolism, involving loss of receptors or blocking of a step between
receptor occupancy and response.
Chemotactic deactivation refers to attractant-
induced loss of migratory function, which is
tested by reexposure of cells to chemotactic fac-
tor (19). Deactivation has been described for
rabbit peritoneal polymorphonuclear leukocytes
(20), human peripheral blood neutrophils (4, 9,
11, 12-14), and eosinophils (21). Human periph-
eral blood monocytes are also subject to deacti-
vation (6, 8). Deactivation of human peripheral
neutrophils has been dissociated into two differ-
ent components. Low concentrations of chemo-
tactic factor lead to inhibition of chemotactic
response that is specific for the attractant,
whereas high concentrations result in inhibition
of the migratory system in a nonspecific manner.
Several possible mechanisms have been pro-
posed to explain these phenomena. Loss of an
esterase activity (20) or damage to the cell by
production of oxidative intermediates (13) or
release of lysosomal enzymes (2) has been sug-
gested for the mechanism of deactivation. Re-
cently, specific deactivation ofhuman peripheral
blood neutrophils has been shown to correlate
with loss of specific cell surface receptors for the
attractant (16, 17). In this report, we show the
dynamics of deactivation of human peripheral
blood monocytes. Only specific deactivation was
observed even when high concentrations of at-
tractant or relatively long incubation times were
used. We also show that, in contrast to human
neutrophils, human monocytes are able to re-
cover from deactivation.
MATERIALS AND METHODS
Cell preparation. Blood was drawn from healthy
donors and heparinized. Mononuclear cells were iso-
lated by the method of Boyum (3). Blood was diluted
with an equal volume of Dulbecco phosphate-buffered
saline without calcium or magnesium, and 35 ml of
diluted blood was underlaid with 15 ml of Ficoll-Paque
(Pharmacia Fine Chemicals, Inc., Piscataway, NJ.).
After centrifugation at 400 x g for 40 min at 20°C, the
interface cell layer was removed and washed twice
with Gey balanced salt solution containing 2% bovine
serum albumin (Cohn fraction V) (Gey-BSA; National
Institutes of Health Media Unit, Bethesda, Md.). The
cell suspension contained 15 to 35% monocytes, 65 to
85% lymphocytes, and less than 1% granulocytes. Vi-
ability was better than 99%, as measured by trypan
blue dye exclusion. Total and differential counts were
made for the final washed preparations. Total leuko-
cyte recovery was 1 x 106 to 3 x 10' cells per ml of
whole blood. Differential counts were made after stain-
ing cell suspensions with euchrysin 3RX (Roboz Sur-
gical Instruments Co., Washington, D.C.) and observ-
ing them with a fluorescence microscope. These num-
bers were used to standardize the cell number added
per well.
Chemotactic factors. N-Formylmethionylleucyl
phenylalanine (FMLP) was purchased from Sigma
Chemical Co., St. Louis, Mo. Stock solutions (10-3 M)
were prepared in either ethanol or dimethyl sulfoxide
and stored at -20°C. Human serum-derived comple-
ment component C5a was prepared by a modified
procedure of Fernandez and Hugli (7) as described
previously (6). Briefly, fresh serum was incubated with
zymosan (Mann Research Laboratory) in the presence
of E-aminocaproic acid (Sigma Chemical Co.). C5a was
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then purified by consecutive chromatography on CM
Sepharose Cl 6B (Pharmacia Fine Chemicals Inc.) and
Sephadex G-100. The final preparation was stored as
a solution in phosphate-buffered saline at -20°C.
Deactivation procedure. Cell preparations were
diluted to concentrations of 1 x 105 to 2 x 105 mono-
cytes per ml of Gey-BSA in 50-ml polypropylene tubes
(no. 25335; Corning Glass Works, Corning, N.Y.).
FMLP stock solution was diluted in Gey-BSA so that
it could be diluted 1:100 into the cell suspensions.
Standard incubation time for deactivation was 45 min
unless indicated otherwise. After incubation, the cells
were washed twice in medium at room temperature,
and total and differential counts were made for the
final suspensions.
For recovery experiments, the protocol was slightly
changed. Cells to be tested for recovery at 0°C were
put in ice immediately after deactivation, washed with
cold medium, and centrifuged in the cold. Cells for
testing at 37°C were washed and centrifuged at room
temperature and then incubated at 37°C.
For time courses of deactivation and recovery from
deactivation, cells were kept at the concentrations
used for deactivation and tubes were frequently
shaken. At the indicated times, samples were removed
from the tubes and cells were centrifuged at 200 x g.
Pellets were then suspended in Gey-BSA in 1/10 of
the original sample volume. This suspension usually
contained 1 x 106 to 2 x 106 monocytes per ml and
was used for the chemotaxis assay.
Control cell suspensions were subjected to the iden-
tical protocol, but no FMLP was added for deactiva-
tion.
Chemotaxis assay. Chemotaxis was assayed in a
multiwell chamber as described previously (5). Bottom
wells were filled with 25 pl of attractant solutions in
Gey-BSA. A Nuclepore filter sheet (Neuroprobe Inc.,
Bethesda, Md.; Polyvinylpyrrolidone coated, 10 tim
thick, 5-,um hole size) was placed over the wells. Gasket
and top plate were assembled, and 50 pl of cell suspen-
sion containing 50,000 to 100,000 monocytes, depend-
ing on the experiment, was added to each top well.
Chambers were incubated in moist air containing 5%
carbon dioxide for 90 min. After incubation, chambers
were disassembled and filters were removed. Cells
remaining on the top side were wiped off; filters were
immersed in methanol for 15 s and then stained in
Diff-Quick (Harleco, Gibbstown, N.J.). The number of
cells per millimeter squared was counted with an im-
age analyzer (between 1,500 and 3,000). With optimal
concentrations of FMLP or C5a, 20 to 40% of the
monocytes migrated toward the attractant, depending
on the donor (6). These numbers were used to calcu-
late percentage of control migration. Assay points
were performed in triplicate, and the standard error of
the mean was not greater than 15%.
RESULTS
Dependence of degree of chemotactic
deactivation on dose of chemotactic factor.
Monocytes were incubated at 370C in various
concentrations ofFMLP to determine the range
over which deactivation occurred. The cells were
then washed, checked by trypan blue exclusion
for viability (better than 99%), and tested for
chemotaxis to FMLP and C5a. In all experi-
ments, C5a served two purposes: as an indicator
of cell viability and unimpaired migratory mech-
anism and, more important, as a discriminator
between specific and nonspecific deactivation.
The extent of deactivation, as measured by re-
sponses to optimal concentrations of FMLP and
C5a, depended upon the concentration ofFMLP
used to deactivate (Fig. 1). An FMLP concentra-
tion of lo-8 M resulted in about 60% deactiva-
tion. Deactivation was complete at a concentra-
tion of 10-' M. The response to C5a remained
unchanged, except possibly at 10' M, the high-
est concentration of FMLP used. This indicates
that deactivation was specific and that cell dam-
age, at least as measured by chemotactic re-
sponse, did not occur.
Deactivation did not lead to a shift in concen-
tration of peptide needed for maximal chemo-
tactic response. Dose responses for treated cells
still capable of responding to the deactivating
attractant were measured from 10-9 to 10-6 M,
and the location of the response peak was the
same as for the control.
The cell concentration used in deactivation
experiments was between 1 x 105 and 2 x 105
monocytes per ml. Deactivation in suspensions
with higher monocyte densities was unsuccess-
ful; this was presumably due to loss of chemo-
tactic factor, since supernatants of these suspen-
sions showed decreased chemotactic activity.
Time course of deactivation. Monocytes
were incubated with 10-7M FMLP or in medium
alone at 37°C. At intervals indicated in Fig. 2,
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FIG. 1. Dose-dependent specific deactivation of
human monocytes. Mononuclear cells at a density of
2 x I05 monocytes per ml were incubated in FMLP
solutions or medium at 37°C for 45 min. After two
washes in Gey-BSA, monocyte chemotactic response
to 10-8 M FMLP and a 1:800 dilution of C5a stock
solution was measured. Error bars represent stan-
dard errors of the mean for triplicate assay wells.
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FIG. 4. Recovery of human monocytes from deac-
tivation. Cells were incubated at 37°C with 10'- M
FMLP or medium. After incubation, cells were
washed twice to remove FMLP and divided into two
portions each. One set of cells, incubated in FMLP or
medium, was kept at 0°C (A), and one was kept at
37°C (B). At various times monocytes were tested for
chemotactic response to FMLP (10-7 and 10-8 M) and
to a 1:500 dilution of C5a. The figure combines two
experiments. One experiment, in which the cell den-
sity during recovery was 2 x 106/ml, represents times
of20 min and 5 h 10 min. The remaining time points
are for the other experiment, in which cell density
was 2 x 105/ml.
blood monocytes with FMLP as chemoattrac-
tant. Deactivation, or loss of chemotactic re-
sponsiveness after prior exposure to chemoat-
tractants, did not occur at 00C even after rela-
tively long incubation periods. It proceeded very
rapidly at 370C, with almost total deactivation
after 20 to 30 min of incubation. Deactivation
and chemotaxis were also evident at room tem-
perature (data not presented). The degree of
deactivation was dependent upon the dose of
attractant used, with a peptide concentration of
108 M leading to about 60% deactivation. Not
only an optimal concentration of peptide but
also a minimal absolute amount per cell was
necessary. With monocyte concentrations of
about 2 x 106 per ml, deactivation under the
standard conditions (10-7 M FMLP) did not
occur (data not shown). A likely explanation for
this phenomenon is digestion of the peptide on
or in the monocyte, since supernatants of these
deactivations showed decreased chemotactic ac-
tivity, indicating loss of chemotactic factor. Al-
though release of FMLP split products has not
yet been reported for monocytes, it has been
shown for other cells (1, 16).
The deactivation of monocytes was always
specific. In all experiments, we used the response
to an unrelated attractant, C5a, as a control for
specificity and functional capacity of the cell.
Even at very long incubation times or at concen-
trations of attractant that were 100-fold higher
than the concentration required for 90% deacti-
vation, nonspecific deactivation was not ob-
served. We have shown in a previous report (6)
that this is also true for other attractants used
for deactivation. This is in sharp contrast to the
behavior of polymorphonuclear cells from rab-
bits and humans (12-14). Polymorphonuclear
cell deactivation has been reported to have a
specific and a nonspecific component, depending
on the concentration of chemotatic factor used
for deactivation. Only 40 to 50% deactivation
could be achieved, and specific and nonspecific
components could not be clearly separated. The
nonspecific event leading to decreased cell mo-
tility was ascribed to several factors, such as (i)
depletion of an enzyme or proenzyme pool or (ii)
damage of the cell caused by oxidative interme-
diates. These mechanisms do not seem to oper-
ate in monocytes; if they do, the capacity of the
cell for movement is not affected. Production of
oxidative intermediates in monocytes has been
shown to be poor compared with neutrophils
(10, 15), and measured oxygen uptake by mon-
ocytes upon stimulation with FMLP is also very
small (data not shown). Deactivation of mono-
cytes for a specific attractant with retention of
responsiveness to other attractants suggests that
deactivation is at the level of the attractant
receptor or at some point in the path leading to
directional movement before the common path-
way activated by all attractants. Since deacti-
vation did not occur at 00C, but required a
metabolizing cell, binding to receptors by at-
tractant appears to be insufficient for deactiva-
tion. Binding studies with labeled FMLP showed
that the peptide was specifically bound at 0°C.
The amount bound within 30 min of incubation
was 70% of the amount bound at 220C (W. Falk,
L. Harvath, and E. J. Leonard, manuscript in
preparation).
It has been reported for neutrophils and hu-
man monocytes (17; J. J. Muscato, J. E. Niedel,
and J. B. Weinberg, Blood 54:89a, 1979) that
incubation with chemotactic factor is followed
by aggregation and internalization of the recep-
tor-attractant complex. This is an energy-de-
pendent phenomenon and is inhibited by low
temperatures. This finding provides a plausible
mechanism for specific deactivation in that it
leads to depletion of the cells of receptors for
that specific attractant. Into that scheme fits our
observation that monocytes recovered from spe-
cific deactivation within about 6 h. The recovery
was inhibited by low temperature. This time
period correlates with the time monocytes need
to recover from depletion of immunoglobulin G
receptors (18), which has been shown to be
approximately 6 h also. It does not mean that
there must be a link between immunoglobulin G
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receptor and FMLP receptor, but this time span
seems to be sufficient to rebuild the surface of
the cell and elaborate new receptors. Experi-
ments are in progress to correlate deactivation
and chemotaxis with disappearance and reap-
pearance of receptors on the surface.
LITERATURE CITED
1. Aswanikumar, S., E. Schiffman, B. A. Corcoran, and
S. M. Wahl. 1976. Role of a peptidase in phagocyte
chemotaxis. Proc. Natl. Acad. Sci. U.S.A. 73:2439-2442.
2. Becker, E. L., J. H. Showell, P. M. Henson, and L. S.
Hsu. 1974. The ability of chemotactic factors to induce
lysosomal enzyme release. 1. The characteristic of the
release, the importance of surfaces and the relation of
the release to chemotactic responsiveness. J. Immunol.
112:2047-2054.
3. Boyum, A. 1962. Isolation of mononuclear cells and gran-
ulocytes from human blood. Scand. J. Clin. Lab. Invest.
Suppl. 21:77-89.
4. Craddok, P. R., J. Fehr, and H. S. Jacob. 1976. Com-
plement mediated dysfunction in paroxysmal nocturnal
hemoglobinuria. Blood 47:931-939.
5. Falk, W., R. H. Goodwin, Jr., and E. J. Leonard. 1980.
A 48-well micro chemotaxis assembly for rapid and
accurate measurement of leucocyte migration. J. Im-
munol. Methods 33:239-247.
6. Falk, W., and E. J. Leonard. 1980. Human monocyte
chemotaxis: migrating cells are a subpopulation with
multiple chemotaxin specificities on each cell. Infect.
Immun. 29:953-959.
7. Fernandez, H. N., and T. E. Hugli. 1976. Partial char-
acterization of human C5a anaphylatoxin. I. Chemical
description of the carbohydrate and polypeptide portion
of human C5a. J. Immunol. 117:1688-1694.
8. Ho, P. P., D. L. Young, and G. L. Southard. 1978.
Methylester of N-formylmethionyl-leucyl-phenylala-
nine: chemotactic responses of human blood monocytes
and inhibition of gold compounds. Arthritis Rheum. 21:
133-136.
9. Issekutz, A. C., and W. D. Biggar. 1977. Influence of
serum-derived chemotactic factors and bacterial prod-
ucts on human neutrophil chemotaxis. Infect. Immun.
15:212-220.
10. Johnston, R. B., Jr., J. E. Lehmeyer, and L. A. Guth-
rie. 1976. Generation of superoxide anion and chemi-
luminescence by human monocytes during phagocytosis
and on contact with surface bound immunoglobulin G.
J. Exp. Med. 143:1551-1556.
11. Miller, M. E. 1974. Chemotaxis and random mobility.
Clinical and biological differentiation. Antibiot. Chem-
other. 19:338-349.
12. Nelson, R. D., V. D. Fiegel, M. J. Herron, and R. L.
Simmons. 1980. Chemotactic deactivation of human
neutrophils. Relationship to loss of cytotaxin receptor
function and temporal nature of the phenomenon. RES
J. Reticuloendothel. Soc. 28:285-294.
13. Nelson, R. D., R. T. McCormack, V. D. Fiegel, M. J.
Herron, R. L. Simmons, and P. G. Quie. 1979. Chem-
otactic deactivation of human neutrophils. Possible re-
lationship to stimulation of oxidative metabolism. In-
fect. Immun. 23:282-286.
14. Nelson, R. D., R. T. McCormack, V. D. Fiegel, and R.
L. Simmons. 1978. Chemotactic deactivation of human
neutrophils. Evidence for nonspecific and specific com-
ponents. Infect. Immun. 22:441-444.
15. Nelson, R. D., E. L. Mills, R. L. Simmons, and P. G.
Quie. 1976. Chemiluminescence response of phagocy-
tizing human monocytes. Infect. Immun. 14:129-134.
16. Niedel, J. E., S. Wilkinson, and P. Cuatrecasas. 1979.
Receptor mediated uptake and degradation of 125I-
chemotactic peptide by human neutrophils. J. Biol.
Chem. 254:10700-10706.
17. Niedel, J. E., I. Kahane, and P. Cuatrecasas. 1979.
Receptor mediated internalization of fluorescent chem-
otactic peptide by human neutrophils. Science 205:
1412-1414.
18. Schmidt, M. E., and S. D. Douglas. 1972. Disappearance
and recovery of human monocyte IgG receptor activity
after phagocytosis. J. Immunol. 109:914-917.
19. Ward, P. A., and E. L Becker. 1967. Mechanism of
inhibition of chemotaxis by phosphonate esters. J. Exp.
Med. 125:1001-1020.
20. Ward, P. A., and E. L. Becker. 1968. The deactivation
of rabbit neutrophils by chemotactic factor and the
nature of the activable esterase. J. Exp. Med. 127:693-
709.
21. Wasserman, S. I., D. Withmer, E. J. Goetzl, and K. J.
Austen. 1975. Chemotactic deactivation of human eo-
sinophils by the eosinophil chemotactic factor of ana-
phylaxis. Proc. Soc. Exp. Biol. Med. 148:301-306.
INFECT. IMMUN.
 at R
EG
ENSBURG
 on July 15, 2009 
iai.asm
.org
D
ow
nloaded from
 
